Meryem Aslı Tuncer, Murat Kürtüncü, Murat Terzi, Uğur Uygunoğlu, Cansu Göncüoğlu, Ayşe Nur Yüceyar, Özgül Ekmekçi, Recai Türkoğlu, Aysun Soysal, Mesrure Köseoğlu, Cavit Boz, Yeşim Beckmann, Ömer Faruk Turan, Duruhan Meltem Demirkıran, Firdevs Gülşen Akman, Burcu Altunrende, İlknur Aydın Cantürk, Erkingül Birday, Abdulcemal Özcan, Özden Kamişli, Nazire Pinar Acar Özen, Rabia Gökçen Gözübatik Çelik, Fatma Belgin Balcı, Hüsnü Efendi, Cansu Sarıkaya, Aylin Akçalı, Münire Kılınç Toprak, Sibel Canbaz Kabay, Ferah Kızılay, Mustafa Serhan Sevim, Gülcan Baran Gazaloğlu, Caner Feyzi Demir, Ferhat Balgetir, Nefati Kıylıoğlu, Hande Sarıahmetoğlu, Çağcan Ölmez, Kamil Mavi, Süha Yüksel, Nihal Işık, Sabahattin Saip, Rana Karabudak, Aksel Siva, Mefküre Eraksoy
BACKGROUND: During multiple sclerosis (MS) treatment different modes of action such as lateral (interferon beta to glatiramer acetate or glatiramer acetate to interferon beta) or vertical (interferon beta/glatiramer acetate to fingolimod) drug switch can be performed. This study aims to investigate the clinical effectiveness of switching from the first-line injectable disease modifying treatments (iDMTs) to fingolimod (FNG) compared to switching between first-line iDMTs. METHODS: This is a multicenter, observational and retrospective study of patients with relapsing-remitting MS who had lateral and vertical switch...
February 2023: Turkish Journal of Medical Sciences